In the updated analysis of the TRIBE study, Chiara Cremolini and colleagues1 reported that patients treated with FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab (the experimental group) had significantly better overall survival in patients with metastatic colorectal cancer compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab (the control group). In accordance with a general consensus that administration of all three cytotoxic drugs (ie, fluorouracil, oxaliplatin, and irinotecan) can maximise overall survival in advanced colorectal cancer,2 the patients in the control group were supposed to receive oxaliplatin-based chemotherapy at the initial diagnosis of disease progression.
TRIBE study: are all three cytotoxic drugs crucial? - Authors' reply
LOUPAKIS, FOTIOS;CREMOLINI, CHIARA;ROSSINI, DANIELE;FALCONE, ALFREDO
2015-01-01
Abstract
In the updated analysis of the TRIBE study, Chiara Cremolini and colleagues1 reported that patients treated with FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab (the experimental group) had significantly better overall survival in patients with metastatic colorectal cancer compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab (the control group). In accordance with a general consensus that administration of all three cytotoxic drugs (ie, fluorouracil, oxaliplatin, and irinotecan) can maximise overall survival in advanced colorectal cancer,2 the patients in the control group were supposed to receive oxaliplatin-based chemotherapy at the initial diagnosis of disease progression.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
